Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its pipeline.
The post Roche Gains Rights to Hanmi Obesity Drug That Reduces Fat, Preserves Muscle appeared first on MedCity News.
Bengali (Bangladesh) · 
English (United States) ·